表紙:急性中耳炎 (AOM) 治療薬の世界市場の動向・予測 (2022年~2028年):薬剤タイプ・製剤・エンドユーザー・地域別
市場調査レポート
商品コード
1084350

急性中耳炎 (AOM) 治療薬の世界市場の動向・予測 (2022年~2028年):薬剤タイプ・製剤・エンドユーザー・地域別

Acute Otitis Media Treatment Market, by Drug Type, Formulation, End User, and Region - Global Trends, and Forecast, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 178 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
急性中耳炎 (AOM) 治療薬の世界市場の動向・予測 (2022年~2028年):薬剤タイプ・製剤・エンドユーザー・地域別
出版日: 2022年05月29日
発行: Coherent Market Insights
ページ情報: 英文 178 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

急性中耳炎 (AOM) 治療薬の市場は、AOMの増加傾向が主な要因となると予想されています。また、最近の新薬の発売やFDAの承認も、近い将来の市場成長を促進すると予想されています。

当レポートでは、世界の急性中耳炎 (AOM) 治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、技術動向、アンメットニーズ、規制シナリオ、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提因子

第2章 市場概要

第3章 市場力学・法規制・動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析
  • 技術動向
  • アンメットニーズ
  • 規制シナリオ
  • 最近の製品承認/発売
  • 技術の進歩
  • PEST分析
  • ポーターのファイブフォース分析

第4章 世界の急性中耳炎 (AOM) 治療薬市場:薬剤タイプ別

  • 市場シェア分析
  • 前年比成長分析
  • 抗生物質
  • 非ステロイド性抗炎症薬
  • 鎮痛剤
  • 麻酔薬

第5章 世界の急性中耳炎 (AOM) 治療薬市場:製剤別

  • 市場シェア分析
  • 前年比成長分析
  • 経口剤
  • 局所剤

第6章 世界の急性中耳炎 (AOM) 治療薬市場:流通チャネル別

  • 市場シェア分析
  • 前年比成長分析
  • 病院
  • 小売薬局
  • オンライン薬局

第7章 世界の急性中耳炎 (AOM) 治療薬市場:地域別

  • 市場シェア分析
  • 前年比成長分析
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • アフリカ

第8章 競合情勢

  • ヒートマップ分析
  • 企業プロファイル
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Abbott Laboratories
  • GlaxoSmithKline plc.
  • Bayer AG
  • Novartis AG
  • Pediapharm Inc.
  • Sanofi S.A.
  • Bristol Myers Squibb Company

第9章 セクション

目次
Product Code: CMI1333

Acute otitis media (AOM) is inflammation of the fluid in the middle ear. AOM is the most common infection and mainly caused in children under the age of 7 years. According to an article published American Family Physician Journal in 2013, around 80% of children will have at least one episode of acute otitis media (AOM) before their school age. AOM is mainly caused by bacteria such as Streptococcus pneumoniae (strep) and Hemophilus influenzae (H. flu) and viruses. Bacteria account for 85% cases of AOM and viruses account for only 15%. AOM is mostly treated with antibiotics usually for 7–10 days and with some analgesic and anesthetic in order to the reduce pain.

Market Dynamics

Increasing prevalence of acute otitis media is expected to be a major driver for growth of the market. Acute otitis media is a very common disease and occurs mostly in children, therefore, increasing prevalence of this disease is expected to increase demand for treatment drugs, thereby positively affecting market growth. According to an article published in The Journal of Laryngology & Otology, in 2013, prevalence of otitis media subtypes is between 7.1–12.8%. Furthermore, recent launches and FDA approvals for new drugs for the treatment of acute otitis media is also expected to drive the market growth in the near future. For instance, in 2015, Otonomy, Inc. received U.S. Food and Drug Administration (FDA) approval for its OTIPRIO (ciprofloxacin otic suspension) indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement. In 2021, Otonomy, Inc. launched OTIPRIO in U.S. market.

Key features of the study:

This report provides in-depth analysis of acute otitis media treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global acute otitis media treatment market  based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

Key companies covered as a part of this study include Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, GlaxoSmithKline plc., Bayer AG, Novartis AG, Pediapharm Inc., Sanofi S.A., and Bristol Myers Squibb Company.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

The global acute otitis media treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the acute otitis media treatment market

Detailed Segmentation:

Global Acute Otitis Media Treatment Market, By Drug Type :

Antibiotics

Nonsteroidal anti-Inflammatory drug

Analgesic

Anaesthetic

Global Acute Otitis Media Treatment Market, By Formulation:

Oral

Topical

Global Acute Otitis Media Treatment Market, By Distribution Channel:

Hospital

Retail pharmacies

Online pharmacies

Global Acute Otitis Media Treatment Market, By Geography:

North America

By Drug Type :

Antibiotics

Nonsteroidal anti-Inflammatory drug

Analgesic

Anaesthetic

By Formulation

Oral

Topical

By Distribution Channel:

Hospital

Retail pharmacies

Online pharmacies

By Country:

U.S.

Canada

Europe

By Drug Type :

Antibiotics

Nonsteroidal anti-Inflammatory drug

Analgesic

Anaesthetic

By Formulation

Oral

Topical

By Distribution Channel:

Hospital

Retail pharmacies

Online pharmacies

By Country:

U.K.

Germany

Italy

France

Spain

Russia

Rest of Europe

Asia Pacific

By Drug Type :

Antibiotics

Nonsteroidal anti-Inflammatory drug

Analgesic

Anaesthetic

By Formulation

Oral

Topical

By Distribution Channel:

Hospital

Retail pharmacies

Online pharmacies

By Country:

China

India

Japan

ASEAN

Australia

South Korea

Rest of Asia Pacific

Latin America

By Drug Type :

Antibiotics

Nonsteroidal anti-Inflammatory drug

Analgesic

Anaesthetic

By Formulation

Oral

Topical

By Distribution Channel:

Hospital

Retail pharmacies

Online pharmacies

By Country:

Brazil

Mexico

Rest of Latin America

Middle East

By Drug Type :

Antibiotics

Nonsteroidal anti-Inflammatory drug

Analgesic

Anaesthetic

By Formulation

Oral

Topical

By Distribution Channel:

Hospital

Retail pharmacies

Online pharmacies

By Country:

GCC

Israel

Rest of Middle East

Africa

By Drug Type :

Antibiotics

Nonsteroidal anti-Inflammatory drug

Analgesic

Anaesthetic

By Formulation

Oral

Topical

By Distribution Channel:

Hospital

Retail pharmacies

Online pharmacies

By Country:

Central Africa

South Africa

North Africa

Company Profiles

Pfizer, Inc.*

Company Overview

Product Portfolio

Financial Performance

Key Strategies

Recent Developments

Eli Lilly and Company

Abbott Laboratories

GlaxoSmithKline plc.

Bayer AG

Novartis AG

Pediapharm Inc.

Sanofi S.A.

Bristol Myers Squibb Company

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Formulation
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Technological Trends
    • Unmet Needs
    • Regulatory Scenario
    • Recent Product Approvals/Launch
    • Technological Advancement
    • PEST Analysis
    • Porter's Five Forces Analysis

4. Global Acute Otitis Media Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Antibiotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Nonsteroidal anti-Inflammatory drug
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Analgesic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Anaesthetic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

5. Global Acute Otitis Media Treatment Market, By Formulation, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Acute Otitis Media Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Hospital
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Retail pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Online pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Acute Otitis Media Treatment Market, By Region, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
    • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
    • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Formulation, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel , 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Abbott Laboratories
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pediapharm Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bristol Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact